Further studies are warranted to identify the underlying biochemical mechanisms affected by the mutations in the allelic variants, and to validate the roles of XPD and XRCC1 genetic polymorphisms as predictors of chemotherapeutic outcome in CRC patients. This evidence concerns the gene XRCC1 and colorectal carcinoma.